In silico solutions for biopharma R&D
Customizable platforms and solutions across the drug discovery value chain from target discovery to therapeutic development
The biopharma industry is in the early stages of a dramatic transformation in how it operates, from the discovery of drugs to clinical trials to clinical operations. This creates an opportunity to develop a framework for rapidly identifying and bringing to market new treatments for diseases. The transformation is happening in three key areas: research and development, clinical trials, and clinical operations.
We refer to this as the computational transformation of biopharma processes. This digital transformation of the core business is important for the next generation of biopharma companies to succeed. The core drivers and capabilities that are key to this transformation include the ability to process large amounts of information (example: genomic data), automation of the information flows, and in silico modeling bringing together AI/ML, chemistry, and biology domains.
A few examples include:
- Successfully managing in silico, in vitro, ex vivo, and in vivo processes for optimal results
- Engaging and automating dry lab and wet lab interactions for optimal results
Reference Architecture and Platform
The following is Aganitha’s reference architecture and its building blocks: from computational infrastructure to pipelining to functional solution components for building Omics models, pipelines, and platforms.